Merck Serono

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

Retrieved on: 
星期四, 四月 25, 2024
Genetics, CMO, Doctor of Philosophy, Boston, Development, Novartis, Pfizer, Operating partner, Functional genomics, CSO, Genome, Associate, Drug discovery, SAB, AbbVie, Baxalta, EVP, GSK plc, Bristol Myers Squibb, GSK, Baylor College of Medicine, University, Harvard Medical School, Therapy, Biotechnology, Inflammation, Hospital, NIH, Michigan State University, Respiratory Medicine, Imperial College London, IPO, Rockefeller University, Spatial, MPH, Genomics, Atlas Venture, Merck Serono, Genentech, University of Birmingham, Senior, Society, Acquisition, Discovery, Sanofi, Baylor University

New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.

Key Points: 
  • New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.
  • The SAB is chaired by Prof. Jim Hughes, Scientific Founder and Non-Executive Director of Nucleome Therapeutics.
  • Dr Russell Greig, Non-Executive Chair of the Nucleome’s Board, said: “We are delighted to have appointed such esteemed experts to the Nucleome team.
  • Steve’s multifaceted background, spanning academia, industry and leadership roles, positions him as a key contributor to Nucleome’s Scientific Advisory Board.

Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release

Retrieved on: 
星期一, 四月 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials, Other Health, USD, Patient, Adenosine, DSM-IV codes, ADPKD, Sumitomo Pharma, Safety, Pharmacokinetics, European Patent Convention, JPY, Merck Serono, Kidney, Male, Adrenoleukodystrophy, VLCFA, EUR, Plasma, Serono, Disease, NASH, Fatty liver disease, Patent, ALD, AMN, POC, Biomarker, Merck, EPO, Pharmaceutical industry

As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.

Key Points: 
  • As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.
  • Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.
  • For territories not covered by its agreement with Sumitomo Pharma, Poxel is in ongoing discussions with potential partners for Imeglimin.
  • Net financial debt (excluding IFRS16 impacts and derivative debts) was EUR 47.4 million as of March 31, 2024, as compared to EUR 45.6 million as of December 31, 2023.

Amid threats to IVF, National Infertility Awareness Week® Brings Awareness Activities Across the Country

Retrieved on: 
星期一, 四月 15, 2024
CVS, Fertility, NIAW, Social media, Woman, Infertility, Human services, Merck Serono, Encompass, IVF, Family, Ferring Pharmaceuticals, Legislation, Movement, Face, First, The Cooper Companies, Birth control

MCLEAN, Va., April 15, 2024 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association (RESOLVE) will recognize National Infertility Awareness Week®, April 21 through April 27, 2024. The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families. RESOLVE will rally the infertility community to share their stories in an effort to raise awareness about the threats to family building options like IVF, the lack of access to family building options and the need for emotional support for the 1 in 6 people who will face infertility. #LeaveYourMark is a message found on the official NIAW website and throughout RESOLVE's social media campaigns.

Key Points: 
  • RESOLVE: The National Infertility Association will recognize National Infertility Awareness Week®, April 21 through April 27, 2024.
  • The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families.
  • MCLEAN, Va., April 15, 2024 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association (RESOLVE) will recognize National Infertility Awareness Week® , April 21 through April 27, 2024.
  • The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families.

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Retrieved on: 
星期四, 三月 21, 2024
University, Sanofi, Therapeutic index, Growth, GSK plc, Rotman School of Management, Merck Serono, Immunotherapy, Partnership, Patient, SAN, Ipsen, Merck, Cancer, Faculty, Society, TU Dresden, Therapy, Institute of technology, SITC, University of Florida

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.
  • “We are excited to welcome Zhen to our board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
  • Dr. Su is currently chief executive officer of Marengo Therapeutics and a member of its Board of Directors.
  • Dr. Su also serves on the board of directors of Karyopharm Therapeutics and as the funding chairperson for the biotech committee of the Society for Immunotherapy of Cancer (SITC).

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Retrieved on: 
星期三, 三月 13, 2024
Development, Gene editing, Growth, Regeneron Pharmaceuticals, Biotechnology, Science and nature, Merck Serono, Patient, Branches of microbiology, Acquisition, Virology, Executive Committee, Max Planck Society, CRISPR Therapeutics, University, Senior, Bayer, Publication, Therapy, Takeda, CRISPR, Amgen, CRSP, Medicine, Pharmaceutical industry

“We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.

Key Points: 
  • “We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.
  • Dr. Rommel currently serves as Executive Vice President, Global Head of Research & Development and a Member of the Executive Committee of Bayer Pharmaceuticals, Inc.
  • He joined Bayer from Roche, where he was most recently Senior Vice President, Global Head of Oncology, Pharma Research and Early Development (pRED).
  • He has authored more than 70 publications, including papers in Science and Nature, and is an inventor or co-inventor of 18 patents.

Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development

Retrieved on: 
星期四, 四月 4, 2024
Merck Serono, Partnership, ADAPT, Patient, Neoplasm, Research, Health care, Merck, Cancer, Doctor of Philosophy, Spacecraft, Senior, Merck Group, Therapy, Machine learning, ADC, Pharmaceutical industry

Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Caris with an upfront payment as well as research funding.

Key Points: 
  • Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Caris with an upfront payment as well as research funding.
  • Merck KGaA, Darmstadt, Germany will receive an exclusive global license to develop, manufacture and commercialize ADC therapeutics for selected targets.
  • Caris Discovery leverages the scale of Caris' core molecular profiling business to discover novel, druggable targets that would be otherwise inaccessible through more traditional approaches.
  • "We are proud to be working closely with Merck KGaA, Darmstadt, Germany, to bring new therapeutic options to cancer patients together."

Inception Fertility™ 2024 Annual Physician Summit: A Celebration of Collaboration, Patient Dedication, and Advancements in Fertility Research

Retrieved on: 
星期四, 三月 14, 2024
Diamond, Health, Prelude, Organon, Learning, Merck Serono, Ferring Pharmaceuticals, Physician, Patient, Mental health, Patient experience, Reproductive medicine, Fertility, Labcorp, Inception, The Cooper Companies, Summit, Family, Parent, Nursing

HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.

Key Points: 
  • Global fertility leader's annual summit brings together physicians, team members across Inception's expansive family of brands
    HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility ™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.
  • This included two full days of learning, team building, collaborating, and the field of reproductive medicine.
  • Panel sessions covered topics related to mental health in fertility care, groundbreaking research studies, and using technology to drive the patient and employee experience, among others.
  • The 2024 Patient Experience Awards included the Patient Experience Outstanding Practice Award, Patient Experience Leader Award, CEO's Patient Experience Emerging Leader Award, and Patient Experience Tenet Leaders Awards.

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Retrieved on: 
星期一, 三月 4, 2024
Merck, Research, Merck Serono, Health care, C4, Merck Group, Therapy, Collaboration, Patient, Development, CCCC, Cancer, Partnership, Pharmaceutical industry

WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has entered into a license and collaboration agreement with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline.

Key Points: 
  • “We look forward to capitalizing on C4 Therapeutics’ experience in advancing degrader candidates targeting disease-causing proteins from discovery to the clinical stage, with the shared goal of improving patient outcomes.”
    Under the terms of the agreement, C4T and Merck KGaA, Darmstadt, Germany, will collaborate to discover two targeted protein degraders against critical oncogenic proteins.
  • C4T has the potential to receive up to approximately $740 million in discovery, regulatory, and commercial milestone payments across the collaboration.
  • As part of the collaboration, C4T will utilize its proprietary TORPEDO® platform to discover degraders targeting the partnership’s oncogenic proteins of interest.
  • Merck KGaA, Darmstadt, Germany, will be responsible for clinical development and commercialization for drug candidates coming out of these programs.

EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits

Retrieved on: 
星期四, 二月 29, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Senior, Merck, Quality of life, Merck Serono, Treatment, Disease, Multiple sclerosis, System, Safety, EDSS, Health care, Bawskee 3.5, SDMT, Patient, Employment, Cladribine, Sclerosis, RMS, Tablet, Merck Group, MRI, Pharmaceutical industry

The first presentation examines the stability or improvement in cognitive processing speed over a two-year period, suggesting the potential of MAVENCLAD to maintain or improve cognitive function in patients with highly active RMS.

Key Points: 
  • The first presentation examines the stability or improvement in cognitive processing speed over a two-year period, suggesting the potential of MAVENCLAD to maintain or improve cognitive function in patients with highly active RMS.
  • Additionally, interim findings from year three of the MAGNIFY-MS extension trial underscore the continued efficacy and safety profile of MAVENCLAD, which is consistent with earlier safety data.
  • These data are being presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024.
  • The post-hoc analysis from 270 patients showed a clinically meaningful benefit in cognitive processing speed in patients treated with MAVENCLAD.

Diakonos Oncology Names Paul Lammers, M.D., Veteran BioPharma Senior Executive, to its Board of Directors

Retrieved on: 
星期二, 二月 20, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Cancer, Merck Serono, Patient, Pharmaceutical industry

Diakonos Oncology Corp. (“Diakonos”), a clinical stage immuno-oncology company, announced today that Paul Lammers, M.D., M.Sc., a distinguished executive with over 35 years of experience in the biotech and pharmaceutical industries, has been named to its Board of Directors.

Key Points: 
  • Diakonos Oncology Corp. (“Diakonos”), a clinical stage immuno-oncology company, announced today that Paul Lammers, M.D., M.Sc., a distinguished executive with over 35 years of experience in the biotech and pharmaceutical industries, has been named to its Board of Directors.
  • "Dr. Lammers' success in leading both private and public biopharma companies, combined with his extensive experience in fundraising, will provide critical experience in guiding our clinical development and commercialization of Diakonos’ unique cancer immunotherapies," said Mike Wicks, Chief Executive Officer of Diakonos.
  • Before Triumvira, he led Mirna Therapeutics as President and CEO, taking the company public on NASDAQ in 2015.
  • “I am deeply honored to join the Diakonos team and contribute to their groundbreaking work in developing dendritic cell vaccines.